Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04919382 | Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | recruiting | Phase 2 | 56 | Dwight OwenOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05713006 | Alectinib Pharmacokinetic in Patients With NSCLC | recruiting | Phase 1 / Phase 2 | 45 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05987644 |
| Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements(DURABLE) |
| recruiting |
| Phase 1 / Phase 2 |
| 56 |
| Joshua PalmerOTHER |
| 1 |
| Apr 8, 2026 |
| clinicaltrials |
| NCT06248606 | Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | recruiting | Phase 2 | 30 | Ryan Gentzler, MDOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07241767 | A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer | recruiting | Phase 2 | 200 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07295821 | Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study(NSCLC) | recruiting | Phase 2 | 60 | AstraZenecaINDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06495125 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 50 | Emory UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07001618 | Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer(IMMUNOLIFE2) | recruiting | Phase 2 | 162 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Vivace Therapeutics, IncINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT07354061 | Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)(TD-ENSEMBLE) | recruiting | Phase 1 / Phase 2 | 20 | Tang-Du HospitalOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07505173 | Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer(HOPE-WBRT) | recruiting | Phase 2 | 74 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06424067 | Phase 2 Study of Fingolimod in Lung Cancers | recruiting | Phase 2 | 38 | Medical University of South CarolinaOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06769126 | Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study | recruiting | Phase 2 | 900 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07055581 | Durvalumab as Consolidation for Patients LS-SCLC | recruiting | Phase 2 | 100 | Qian ChuOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492342 | Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC(K-NADIR) | recruiting | Phase 2 | 30 | Jianxing HeOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05805631 | Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | recruiting | Phase 2 | 23 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05669846 | Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC | recruiting | Phase 2 | 26 | Diwakar DavarOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07218601 | Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer | recruiting | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07336732 | Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations(KANNON-5) | recruiting | Phase 2 | 40 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT07480213 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)(DART-NK-SCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04499053 | Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer | recruiting | Phase 2 | 18 | Georgetown UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07473167 | Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients(TC011) | recruiting | Phase 1 / Phase 2 | 98 | TICAROS Co., Ltd.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07467863 | Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC(DUO-NK-NSCLC) | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05798845 | The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer | recruiting | Phase 2 | 124 | Shanghai Chest HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06681220 | Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC(Relapsed SCLC) | recruiting | Phase 1 / Phase 2 | 166 | VA Office of Research and DevelopmentFED | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06775743 | ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs | recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07198841 | IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation | recruiting | Phase 2 | 48 | Guangdong Association of Clinical TrialsOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06951646 | ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) | recruiting | Phase 2 | 70 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07120282 | Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC | recruiting | Phase 2 | 108 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07202364 | A Study of YL202 in Patients With Advanced Solid Tumors | recruiting | Phase 2 | 100 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07391813 | SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer(SNB-101-101) | recruiting | Phase 1 / Phase 2 | 55 | SN BioScienceINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT01803542 | Stereotactic Radiotherapy (SBRT) of Lung Metastasis(SBRT Lung) | recruiting | Phase 2 | 200 | University Health Network, TorontoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06895031 | Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS(STAR) | recruiting | Phase 2 | 210 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05672108 | Phase II Trial of Lung Chemoemobolization | recruiting | Phase 2 | 30 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05934448 | Pembro Plus CAR T-cell Therapy in R/R in PMBCL | recruiting | Phase 2 | 35 | Jennifer Crombie, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07264816 | A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC | recruiting | Phase 2 | 80 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05068232 | Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) | recruiting | Phase 2 | 49 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06719700 | Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06275360 | Repositioning Immunotherapy in VetArans With Lung Cancer(RIVAL) | recruiting | Phase 2 | 25 | VA Office of Research and DevelopmentFED | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06956690 | A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Hummingbird BioscienceINDUSTRY | 2 | Mar 2, 2026 | clinicaltrials |
| NCT03808337 | Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | recruiting | Phase 2 | 145 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04485286 | Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury | recruiting | Phase 2 | 72 | Massachusetts General HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07110103 | Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC(JACKPOT38) | recruiting | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06918132 | Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer(N-PLANC) | recruiting | Phase 2 | 60 | Mayo ClinicOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Feb 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 8, 2026source: clinicaltrials